Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment. However, cancer cells have developed immune evasion strategies, leading to poor treatment responses. Now, researchers from Japan have identified the transfer of mitochondria with mutated DNA from cancer cells to immune cells as a key mechanism of immune evasion and resistance to immunotherapy. Targeting this transfer could enhance the effectiveness of cancer immunotherapy.

Malignancy Spectrum, a cutting-edge journal dedicated to advancing the field of oncology, presents its latest issue, Volume 1, Issue 4.

This issue delves into the complex and multifaceted nature of cancer, offering a comprehensive exploration of the latest research, clinical findings, and innovative treatments. From the molecular underpinnings of tumor development to the latest breakthroughs in targeted therapies, this issue provides a platform for researchers, clinicians, and scientists to share their insights and discoveries. With a focus on basic and translational research, Malignancy Spectrum aims to bridge the gap between laboratory findings and clinical practice, ultimately improving patient outcomes and quality of life.

Researchers with the Arkansas Agricultural Experiment Station have improved the accuracy of detecting "woody breast" chicken meat using hyperspectral imaging by developing a new machine learning model to analyze the massive amounts of data from the images. 

The results of their research were published in the journal Artificial Intelligence in Agriculture under the title “Neural network architecture search enabled wide-deep learning (NAS-WD) for spatially heterogenous property awared chicken woody breast classification and hardness regression.”

Scientists uncover an enzyme that boosts cancer cell metabolism to fuel growth

Protein disulfide isomerases (PDIs) are essential enzymes that facilitate the proper folding of proteins and maintain protein quality within the endoplasmic reticulum. Dysregulation of PDIs has been correlated with numerous disorders, including cancer and rheumatoid arthritis (RA). E64FC26 (EFC), a small molecule that inhibits a wide range of PDI family members, has shown promise as a therapeutic agent in oncology. However, its effects on RA have not yet been studied. This research investigates the efficacy of EFC as a potential treatment for RA.

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response in the region changes, researchers from Berlin and Heidelberg report in Science Immunology. The detailed insights into cancer progression could advance diagnostics and treatment.